Given that there are no known transcriptional suppressors of the Vmat2 and TH genes or their homologs, the discovery of rcat-1 reinforces the importance of dopamine biosynthesis and release in PD patients and provides a potential therapeutic target [60]. This evidence concerns the gene SLC18A2 and Parkinson disease.